Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome

==========

Ionis Pharmaceuticals has announced positive results from the Phase 3 Balance study of its investigational medicine, olezarsen, for the treatment of adults with familial chylomicronemia syndrome (FCS). The study showed that the 80 mg monthly dose of olezarsen significantly reduced triglycerides in patients with genetically validated FCS at six months. Olezarsen also demonstrated sustained reductions in triglycerides and serum apolipoprotein C-III levels, as well as a reduction in the incidence of acute pancreatitis events compared to placebo. The results were presented at the American College of Cardiology Annual Meeting and published in The New England Journal of Medicine. Ionis is pursuing regulatory approval for olezarsen as a potential breakthrough treatment for FCS.

#IonisPharmaceuticals #Olezarsen #Phase3BalanceStudy #FamilialChylomicronemiaSyndrome #Triglycerides #AcutePancreatitis #AmericanCollegeOfCardiology #TheNewEnglandJournalOfMedicine #RegulatoryApproval